Tema Oncology ETF (CANC)

Assets	$69.20M
Expense Ratio	0.75%
PE Ratio	20.39
Shares Out	2.90M
Dividend (ttm)	$0.73
Dividend Yield	2.86%
Ex-Dividend Date	Dec 11, 2024
Payout Frequency	Annual
Payout Ratio	57.48%

Volume	7,033
Open	25.91
Previous Close	25.84
Day's Range	25.26 - 25.91
52-Week Low	20.10
52-Week High	30.11
Beta	1.00
Holdings	53
Inception Date	Aug 15, 2023

About CANC

Fund Home Page

The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.

• Asset Class: Equity
• Category: Health
• Stock Exchange: NASDAQ
• Ticker Symbol: CANC
• ETF Provider: Tema

Top 10 Holdings

42.24% of assets

Name	Symbol	Weight
Roche Holding AG	RHHBY	4.81%
BridgeBio Pharma, Inc.	BBIO	4.60%
Revolution Medicines, Inc.	RVMD	4.59%
Eli Lilly and Company	LLY	4.49%
Merus N.V.	MRUS	4.49%
Summit Therapeutics Inc.	SMMT	4.11%
AstraZeneca PLC	AZN	4.09%
Novartis AG	NOVN	4.04%
Genmab A/S	GMAB	3.75%
Nuvalent, Inc.	NUVL	3.26%

Dividends

Ex-Dividend	Amount	Pay Date
Dec 11, 2024	$0.72827	Dec 12, 2024
Dec 13, 2023	$0.14911	Dec 15, 2023

Performance

CANC had a total return of -5.07% in the past year, including dividends. Since the fund's inception, the average annual return has been 2.24%.